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Studies on the interactions between SARS-CoV-2 and humoral immunity are funda-
mental to elaborate effective therapies including vaccines. We used polychromatic flow
cytometry, coupled with unsupervised data analysis and principal component analysis
(PCA), to interrogate B cells in untreated patients with COVID-19 pneumonia. COVID-19
patients displayed normal plasma levels of the main immunoglobulin classes, of antibod-
ies against common antigens or against antigens present in common vaccines. However,
we found a decreased number of total and naı̈ve B cells, along with decreased percent-
ages and numbers of memory switched and unswitched B cells. On the contrary, IgM+
and IgM− plasmablasts were significantly increased. In vitro cell activation revealed that
B lymphocytes showed a normal proliferation index and number of dividing cells per
cycle. PCA indicated that B-cell number, naive and memory B cells but not plasmablasts
clustered with patients who were discharged, while plasma IgM level, C-reactive protein,
D-dimer, and SOFA score with those who died. In patients with pneumonia, the derange-
ment of the B-cell compartment could be one of the causes of the immunological failure to
control SARS-Cov2, have a relevant influence on several pathways, organs and systems,
and must be considered to develop vaccine strategies.
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Introduction
COronaVIrus Disease 19 (COVID-19) is caused by a coronavirus,
called severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2), that has been detected in humans at the end of 2019 and
has provoked the pandemic that we all are experiencing. Most
infections are asymptomatic, but some individuals can present
with a wide spectrum of clinical manifestations, ranging from
viral pneumonia to respiratory failure, or can develop an acute
respiratory distress syndrome (ARDS), with reported mortality
rates ranging from 20-90% [1,2]. Different therapies are now
demonstrating benefit, and biological drugs, such as tocilizumab,
that can block the activity of IL-6 seem effective at reducing
mortality [3].
Understanding the pathophysiology of the immune response to
this virus is fundamental to develop targeted therapies and vac-
cines aimed to control and eradicate the virus [4]. The virus mainly
infects airways and alveolar epithelial cells, and can interact with
cells coexpressing the surface receptors angiotensin-converting
enzyme 2 (ACE2) [5] and the type II transmembrane serine pro-
tease TMPRSS2 [6]. The internalization exposes the genomic RNA
to the dsRNA sensing machinery in the cell IRF-3 cascade leading
to the induction of IFNb and the production of secreted IFN-β pro-
tein by DCs [7] while the expression of viroporin 3a triggers the
activation of NOD-like receptor protein 3 (NLRP3) inflammasome
and the secretion of IL-1β in BM-derived macrophages, suggest-
ing the induction of cell pyroptosis [8]. Macrophages recognition
of released damage-associated molecular patterns (DAMPs) or
pathogen-associated molecular patterns (PAMPs) induces a strong
secretion of pro-inflammatory cytokines and chemokines, such
as IL-1β, IFN-γ, M1p-2, among others, that shape the immune
response [9] and polarize T cell toward Th1 response [10]. In
turn, these cells are crucial to prime CD8+ T cells and to help the
differentiation of B cells into antibody-secreting cells and plasma
cells.
In SARS-CoV, a B-cell response arises about 7-10 days after
onset of symptoms, and in 3 weeks some, but not all, patients
can develop neutralizing antibodies [11], first against the viral N
protein, and then for the S protein. However, significant individ-
ual differences exist, since a relevant subset of patients do not
develop a long-lasting immune response to SARS-CoV-2, suggest-
ing that they could undergo reinfection [12]. Moreover, the almost
simultaneous expression of IgM and IgG present in several cases
suggests that the humoral immune response has remarkable pecu-
liarities both in the activation of memory and näıve B-cell subpop-
ulations.
Herein, we asked whether B cells from COVID-19 patients
showed alterations linked to cell exhaustion or activation. We
found a significant increase in plasmablasts, expressing or not
IgM, with a decrease in switched and unswitched memory
B cells. This result is indicative of a rapid expansion of B
cells subset triggered by the cytokine storm, particularly IL-6.
Interestingly, in vitro stimulation of T lymphocytes by specific
stimuli resulted in a secondary, almost nonspecific expansion
of B cells.
Results
COVID-19 patients show a normal pattern of plasma
antibodies
Patients had normal amounts of different classes of Ig, along
with normal amounts of the antibodies that are induced by the
common pathogens or by different vaccines, as described above
(Table 1). At blood collection, in all patients but two we could
detect antibodies against the virus. However, one patient had IgG
only, and in two patients IgG plasma levels were relatively higher
than IgM+ IgA.
COVID-19 patients show changes in the percentage
and absolute number of B cells
To finely characterize peripheral B cells in subjects affected by
COVID-19 pneumonia, we studied patients and controls using
polychromatic flow cytometry. The analysis of the data result-
ing from cytofluorimetric analysis was then performed by using
two complementary methodologies. In the first, we used the clas-
sical approach based upon the two-dimensional recognition of a
given cell type (for example, cells expressing two markers), fol-
lowed by a first gate that was required to identify the population
of interest, followed by sequential gates to identify other markers
such as those of activation or differentiation. Data obtained with
this gating strategy were then analyzed by appropriate, nonpara-
metric statistical tests, and represented in the figures as scatter
plots with means and standard errors of the mean. In the sec-
ond, we performed an unsupervised analysis that considers the
entire, complex scenario presented by B cells. This analytical tech-
nique uses the multidimensional information obtained by Flow-
SOM metaclustering coupled to a dimension-reduction method
such as the Uniform Manifold Approximation and Projection
(UMAP). Heat maps finally report statistical analysis (see Methods
for details).
The gating strategy for the identification of different types of B
cells, performed by previously described classical methods [13], is
shown in Fig. 1. Panel A shows that after a preliminary gate on the
parameters “time” and “viability,” we could identify lymphocytes
on the basis of side scatter and CD45 expression, then we could
exclude aggregates, gate on single cells, and analyze CD19+ B
cells. Among them, we identified those that expressed IgM or IgD,
or both, or that were double negative. Panel B, related to cells that
were negative for both IgD and IgM, shows representative exam-
ples of the populations present among CD21+, CD24+ or CD21−,
CD24− cells. Note that a control donor and a COVID patient had
different percentages of memory switched of plasmablasts. Fig-
ure 1C, related to cells that were IgD− and IgM+, shows that also
the amount of IgM+ plasmablasts (expressing CD27 and CD38)
was different between a patient and a control donor.
The same Fig. 1 indicates the percentages and absolute
numbers of different B-cell populations. Patients and controls
C© 2020 Wiley-VCH GmbH www.eji-journal.eu
Eur. J. Immunol. 2020. 50: 1283–1294 HIGHLIGHTS 1285
Table 1. Anti-SARS-CoV-2 and plasma levels of different antibodies in patients with Covid-19 pneumonia
Patient ID 1 2 3 4 5 6 7 8 9 10 11 Reference Values
Anti-SARS-CoV2
IgG




5.5 38.6 38.2 23.2 13.3 32.5 34.4 4.0 40.6 8.3 5.5 <6 negative; >8
positive
Total IgG 731 1626 1338 914 924 710 808 849 784 739 876 700- 1600 mg/dL
Total IgA 301 141 208 340 254 252 167 460 164 147 131 70-400 mg/dL
Total IgM 43 85 74 131 97 155 81 195 76 187 36 40- 230 mg/dL
Rubella IgG EIA 291 291 291 4 254 47 4 20 76 16 53 >6 positive












9 1 1 1 1 1 2 4 1 2 1 <20 negative
Varicella Zoster
IgG EIA
1050 783 720 2,850 1,320 1,040 884 259 689 274 1620 <50 negative
Varicella Zoster
IgM EIA
0.03 0.01 0.02 0.06 0.05 0.03 0.01 0.01 0.01 0.02 0.01 <0.10 negative
Measle IgG EIA 3630 19 300 19 100 17 700 10 700 1020 3420 17 000 923 1990 16 700 <150 negative
Measle IgM EIA 0.01 0.01 0.01 0.04 0.02 0.01 0.02 0.09 0.01 0.04 0.02 <0.10 negative
Parotitis IgG EIA 0.3 2.58 0.68 0.15 1.06 0.64 1.26 0.36 0.32 0.22 0.79 <0.10 negative
Parotitis IgM EIA 0.05 0.11 0.02 0.13 0.03 0.01 0.28 0.05 0.01 0.03 0.07 <0.10 negative
Influenza A IgG
EIA
5.8 13.3 25.1 23.2 15.7 12.9 17.2 11.7 35.1 9.6 34.5 <8.5 negative
Influenza A IgA
EIA
2.8 1.8 3.7 6.7 2.8 4.4 2.2 4.6 8.8 3.4 17.3 <8.5 negative
Influenza B IgA
EIA
3.3 1.9 2.5 4.5 3.3 1.6 2.4 7.1 3.2 2.4 3.1 <8.5 negative
Influenza B IgG
EIA













0.03 0.01 1.05 1.12 0.09 0.96 1.69 0.06 0.54 0.25 2.29 <0.10 not
protected
had a similar percentages of total or näıve B cells, but in
patients the absolute number was statistically lower (panel D).
An increased percentage, but not number, of transitional B
cells was also found. Patients had lower percentages and abso-
lute numbers of memory switched and memory unswitched B
cells, but similar amounts of memory IgM-only cells (panel
E). Panel F shows that the percentages and absolute numbers
of IgM− plasmablasts, IgM+ plasmablasts, and of total plas-
mablasts were significantly higher in patients when compared to
controls.
Fine detection of B-cell alterations in COVID-19
patients
We used a more sophisticated approach to detect fine changes
occurring within different subpopulations of CD19+ B cells. For
each patient and control, data from 5000 B lymphocytes were
exported and concatenated in a unique matrix. We explored the B-
cell panel by unsupervised analysis using FlowSOM [14]; this per-
forms multivariate clustering of cells based on the self-organized
map (defined “SOM”) algorithm, categorizing cells into relevant
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Figure 1. Identification of different B-cell populations. (A) Gating strategy used to identify B cells expressing IgM or IgD on their plasma membrane.
A first gate was set in living cells and time, then on CD45+ cells, on physical parameters (FSC-H vs FSC-W) to eliminate doublets, then on CD19
that identify B cells. (B) Representative example of the analysis of the expression of CD27 and CD38 on different types of CD19+, IgM−, IgD−
lymphocytes that were double positive or double negative for CD21 and CD24. This analysis was performed to identify memory switched and
IgM− plasmablasts. A COVID patient and a control donor are shown. (C) Representative example of the analysis of the expression of CD27 and
CD38 on different types of CD19+, IgM+, IgD− lymphocytes. This analysis allowes to identify IgM+ plasmablasts. A COVID patient and a control
donor are shown. (D) Percentage and absolute number of CD19+ B cells, naive B cells, and transitional B cells in COVID patients (red) and healthy
donors (black). (E) Percentage and absolute number of memory switched, memory IgM+ only and memory unswitched B cells in COVID patients
(red) and healthy donors (black). (F) Percentage and absolute number of IgM−, IgM+, and total plasmablasts in COVID patients (red) and healthy
donors (black). Data in A-C are from a single experiment representative of 25 phenotypic analysis performed in 14 COVID patients and 11 healthy
donors. Data in E-F are shown as single values (dots), with lines that indicate the mean ± SEM, and represent all the aforementioned analyses in
11 healthy controls (black) and 14 COVID patients (red). Mann–Whitney t-test was used; exact p value is reported in the figure, when significant.
metaclusters based on their surface markers. We first clustered
all individual cells into nine distinct clusters based on the surface
expression marker proteins. Näıve B cells are defined as IgM+,
IgD+, CD24+, CD21+, CD38−, CD27− while transitional B cells are
IgM+, IgD+, CD24+, CD21+, CD38+, CD27−. Memory unswitched
B cells are defined as IgM+, IgD+, CD24+, CD21+, CD38−, CD27+
while memory switched B cells are IgM−, IgD−, CD24+, CD21+,
CD38−, CD27+. Memory IgM only B cells are IgM+, IgD−, CD24+,
CD21+, CD38−, CD27+. Plasmablasts are IgM−/+, IgD−, CD24−,
CD21−, CD38+, CD27+. Finally, we were able to identify a pop-
ulation of B cells called “unswitched CD24+,” which resemble a
population of exhausted B cells as they are CD21− (Fig. 2A, left
panel).
After this, we used a dimensionality reduction method, the
UMAP to distinguish different CD19+ B-cell populations (Fig. 2A,
right panel). It is possible to immediately recognize näıve B cells
(red dots), memory unswitched (blue), memory switched (pink),
as well as IgM− plasmablasts. The number of IgM+ plasmablasts,
even if evident in the left part of the left panel (in orange) was too
low to allow any unsupervised analysis.
As shown in the heat map of Fig. 2B, näıve cells were similar
among patients and controls. On the contrary, significant differ-
ences were present as far as almost all the other B-cell populations
were concerned.
B-cell proliferation was similar in patients and
controls
We could evaluate B-cell proliferation in seven patients and eight
controls (Fig. 3). B cell were indirectly stimulated by the acti-
vation of T cells, that can to produce, among others, cytokines
like IL-2 and IL-6, that in turn induce in vitro B-cell prolifer-
ation. Panel A shows the gating strategy used for this analy-
sis. After a gate on cell dimension, we draw a gate to identify
single cells and exclude doublets, then a gate to exclude dead
cells, and a final gate to identify CD19+ B lymphocytes. Using
CSFE allowed us to investigate either the proliferation index (i.e.
the number of cells that were able to enter into the cell cycle)
or the percentage of dividing cells (i.e. proliferating cells were
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Figure 1. Continued.
able to enter into more rounds of proliferation) (panel B). As
shown in panel C, no differences were found between patients and
controls.
PCA allows the identification of critical biomarkers
associated with clinical outcome
Figure 4 shows that parameters, such as the absolute number of
lymphocytes, platelets, total number of B lymphocytes, different
types of B cells (memory switched and unswitched, memory IgM-
only, transitional, naive), along with pO2/FiO2 and sO2 clustered
with the PCA area of patients who were discharged. On the con-
trary, IgM level, along with well expected clinical and biochem-
ical parameters, such as SOFA score, heart rate, blood pH, CK,
CRP, D-dimer, among others, clustered in the area of patients who
died.
Discussion
To profile the SARS-CoV-2 humoral immune responses, we have
investigated the B-cells compartment of COVID-19 patients with
pneumonia admitted to Infectious Diseases Clinics (Modena,
Northern Italy) in March-April 2020. All patients were lym-
phopenic, but most did not require invasive ventilation and did
not suffer from too advanced disease. Three of them, however,
died between 13 and 29 days after admission; in all patients,
the analyses here reported were performed 2-4 days after admis-
sion. We found significant and global alterations in the B-cell
compartment that underline the immune system’s effort to make
up for lymphopenia with the increase in transitional B cells and
plasmablasts, besides the cytokine storm and the functional and
phenotypic alterations of the T-cell compartment that we have
recently described in this group of patients [14]. Of note, mem-
ory B cells, that are supposed to remain stable or slightly increase
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Figure 1. Continued.
from 20 to 80 years [15,16], in our patients were significantly
lower than those of controls, who were younger. This further
evidences how deep was the B-cell impairment that we have
found.
Based on previous studies, immediate, primary inflammatory
responses occurs early after a viral infection, and is mainly driven
by an active viral replication. During coronavirus infection, the
host response is associated with a viral-mediated downregulation
and shedding of the virus-specific ACE-2 receptor [17]. Several
molecular mechanisms are implicated in virus spreading, and obvi-
ously in the last months the peculiarity of the immune response to
SARS-CoV-2 has been under deep investigation all over the world.
However, little consideration has been dedicated to B cells and
their capacity to secrete antibodies.
TNF-α and IL-6 are among the most represented cytokines in
plasma from COVID-19 patients [14]. Both are involved in epithe-
lial damage and lung fibrosis, but can also modulate B-cell dif-
ferentiation, lifespan, and activation. IL-6 and TNF-α cooperate at
different levels in the regulation of B-cell life and activity, acting
sequentially in the B-cells immune response [18-24]. Recently, we
have described the characteristics of cytokine storm in a group of
39 patients with COVID-19 pneumonia that included also those
here described [14]. In these patients, extremely high plasma lev-
els of TNF and IL-6 were detected, but, likely because of the rel-
atively low number of patients studied, we found no significant
correlations between the number or the percentage of different
B-cell populations and plasma levels of these cytokines (data not
shown).
Likely, the presence of IgM and IgG observed in COVID-
19 patients could be the result of antibodies produced by
plasmablasts, which, to some extent, can be induced by a T-cell-
independent Ig switch, typically limited to IgG3. Since no assays
are currently available to investigate specific IgG subclasses,
further studies are needed to confirm this aspect and clarify its
importance. The increased presence of plasmablasts in patients
suggests the involvement of innate B cells in the production of
antibodies, along with the findings that in a few cases IgG, but
not IgM were present in the plasma of recently infected patients.
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Figure 1. Continued.
This phenomenon advocates the expansion and secretion of
immunoglobulins by pre-existing memory B-cells specific for
a coronavirus different from SARS-CoV-2. Further studies are
needed to better clarify this aspect.
We noted an increase in the percentage, but not in the abso-
lute number of transitional cells (CD24++, CD38++), relatively
immature elements that are migrating from the BM to peripheral
lymphatic organs, where they develop into mature-näıve B cells
(CD24+, CD38+). It remains to be established whether the rela-
tive expansion of these immature cells, along with that of IgM+
plasmablasts plays a role in generating or not an effective anti-
SARS-CoV2 immune response.
We are well aware that our study has some limitations. First,
we could investigate B-cell phenotype in a relatively low num-
ber of patients. Second, the age of controls was lower, but it has
to be underlined that: (i) in the lockdown period, aged persons
could not leave home, could not donate blood, and we had to
study those volunteers who were available in our hospital; (ii) it
was not allowed, nor safe to go and collect blood in protected
structures for aged individuals; (iii) even if the age of patients
was higher than that of controls, the level of their memory B cells
was significantly lower, although we would have expected other-
wise. Third, we could perform functional analyses only in a few
patients, who however showed the same proliferative capacity of
controls. Fourth, due to the low number of patients, we could not
find significant correlations between B-cell parameters and clinical
outcome. However, the PCA-based approach showing the coclus-
tering of B-cell populations, biochemical parameters, and crucial
clinical endpoints (such as survival or death) further underlines
the importance of the B-cell compartment, especially as far as
memory cells are concerned.
In conclusion, our study provides novel contributions to the
understanding of the breadth and kinetics of B-cell responses in
COVID-19 patients. We show that the recruitment of partially
mature B cells could indicate their exhaustion, as a resulting
from the exaggerated immune activation that we have already
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Figure 2. Unsupervised analysis of the B-cell compartment reveals profound alterations in COVID patients. (A) Left: heatmap representing
different B-cell clusters identified by FlowSOM, with relative identity and percentages in all healthy controls and COVID-19 patients. The colors in
the heatmap represent the median of the arcsinh, 0-1 transformed marker expression calculated over cells from all the samples, varying from black
for lower expression to yellow for higher expression. Each cluster has a unique color assigned (bar on the left). CONTROL=11 donors, COVID=14.
(A) Right: Uniform Manifold Approximation and Projection (UMAP) representation of the B-cell landscape. Each color is assigned according to
the cluster identification palette. (B) Differential analysis between control (color:salmon) and COVID-19 patients (green). The heatmap represents
arcsine-square-root transformed cell frequencies that were subsequently normalized per cluster (rows) to mean of zero and standard deviation
of one. The color of the heatmap varies from pale blue indicating relative under-representation to yellow, indicating relative over-representation.
Bar and numbers at the right indicate significant differentially abundant clusters (green) and adjusted p-values. Clusters are sorted according
to adjusted p-values, so that the cluster at the top shows the most significant abundance changes between the two conditions. Due to the low
number of cells, the analysis of IgM+ plasmablasts was not possible (lower line, N.A.: not available). DiffCyt package was used to perform statistical
analyses. This analysis has been performed on the raw and ungated data regarding the identification of B cells in 25 blood samples, obtained from
14 COVID patients and 11 healthy donors.
described [14]. We also propose that B cells, especially plas-
mablast, should be considered in the clinical evaluation and
stratification of COVID-19 patients with different disease severity.
Our data could be useful to design personalized therapeutical
approaches or new interventions, or help in designing a vaccine.
In this case, vaccination strategies should take into account not
only the need to induce the production of neutralizing antibodies
against the virus, but also the development of a long-standing,
effective immunological memory and, possibly, the smooth-




This is a case-control, cross-sectional, single-center study,
approved by the local Ethical Committee (Area Vasta Emilia
Romagna, protocol number 177/2020, March 10, 2020). Each
participant provided informed consent and all clinical investiga-
tion have been conducted according to the Declaration of Helsinki
principles. A total of 14 COVID-19 patients with pneumonia were
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Figure 3. B-cell proliferation was similar in healthy controls and COVID patients. (A) Representative example (out of 15 experiments) showing the
gating strategy used to identify B cells after 6 days of PBMC colture in the presence of anti-CD3 plus anti-CD28 mAbs and IL-2. A first gate was
set on physical parameters, then on FCS-A abd FSC-W to eliminate doublets, that on live-death plus annexin V to eliminate dead cells, then on
CD19+ events. These cells were then analyzed in panel B. (B) Representative example of the analysis of in vitro B-cell proliferation by the method
of CSFE that allows the identification of dividing cells and proliferation index. The gates depicted in the upper panels and the bar in the lower
panels identify proliferating cells. (C) Control donors (black dots) and COVID patients (red) showed similar amounts of B cells able to proliferate
after in vitro stimulation. Mann–Whitney t-test was used; exact p value is reported in the figure, when significant. Data in C are shown as single
values (dots), with lines that indicate the mean ± SEM, and represent all the aforementioned analyses in eight healthy controls (black) and seven
COVID patients (red).
included in the study (mean age 62 years, range 37-81). Three of
them died, 11 were discharged after a few days (see Supporting
information Table S1). Patients were compared to 11 healthy sub-
jects (medical doctors or sanitary personnel) matched for gender,
with a mean age of 43 years (range 27-61).
We recorded demographic data, medical history, symptoms,
signs, temperature, and main laboratory findings from each
patient. The total number and type of leukocytes in periph-
eral blood were analyzed by hemocytometer, according to rou-
tine methods. The main clinical and hematological data of these
patients are reported in the Supporting information Tables S1-5.
Some of them (i.e. patients 1, 2, 3, 9, 12, 13, 15-17) have already
been described in a previous analysis of T-cell compartment and
cytokine storm in subjects with COVID-19 pneumonia [14].
Blood collection and PBMC isolation
Twenty milliliters of blood was collected in vacuette containing
EDTA and immediately processed according to biosafety rules
[25]. Isolation of PBMC was performed by using Ficoll–Paque
according to standard procedures [15]. PBMC were stored in liq-
uid nitrogen in FBS added with 10% DMSO until analysis. Plasma
was then collected, centrifuged twice, and stored at −80°C until
use.
In 11 patients, we could measure by standard methods the
total amount of IgM, IgG, and IgA, along with the presence of
IgM and IgG antibodies against rubella, herpes simplex type 1
and 2, varicella-zoster, measles, parotitis, influenza A and B, Bor-
detella pertussis, and, in the case of tetanus toxoid, IgG only.
Finally, we measured anti-SARS-CoV2 antibodies, by using Vircell
COVID-19 ELISA IgM+ IgA and COVID-19 ELISA IgG, as indicated
by the manufacturer (https://en.vircell.com/products/COVID-19-
elisa/). Values are expressed as antibody index= (sample OD/cut-
off serum mean OD) × 10.
B-cell immunophenotype by polychromatic flow
cytometry
Thawed PBMC were stained with viability marker Promokine IR-
840 (PromoCell GmbH, Heidelberg, Germany) for 20 min at room
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Figure 4. PCA shows that critical biomarkers and B cells are associated with clinical outcome. Absolute number of lymphocytes, platelets, total
number of B lymphocytes, different types of B cells, pO2/FiO2, and sO2 were associated with patients who were discharged (N = 11). On the
contrary, IgM level, SOFA score, heart rate, blood pH, CK, CRP, D-dimer, among other clinical parameters, are localized in the area occupied by
patients who died (N = 3). The areas circumscribed by the ellipses, where the colred dot indicates the center of the ellipse, represent the PCA space
of the clinical events. Length and direction of the arrows indicate the weight and correlation that each parameter has in moving the center of the
ellipse. The first two principal components accounted for >40% of the total data variance, and can locate in separate 2-D areas patients who died
during the hospitalization from those who were discharged. Variables that lies in a given area of the plot are negatively correlated to those that
lie on the opposite part of the plot.
temperature in PBS. One million PBMC were washed with FACS
buffer and stained with DuraClone IM B cells containing the fol-
lowing lyophilized directly conjugated mAbs: IgD-FITC, CD21-PE,
CD19-ECD, CD27-PC7, CD24-APC, CD38-AF750, IgM-PB, CD45-
KrO. Cells were washed with FACS buffer and acquired at Cytoflex
LX flow cytometer (Beckman Coulter, Hialeah, FL). A minimum
of 500 000 cells was acquired on a CytoFLEX LX flow cytometer
(Beckman Coulter) according to the state of the art methodology
[25,26]. All reagents used in this study are reported in Supporting
information Table S6.
Representation of high parameter flow cytometry
Flow Cytometry Standard (FCS) 3.0 files were imported into
FlowJo software version 9 (Becton Dickinson, San Josè, CA), and
analyzed by standard gating to remove aggregates and dead cells,
and identify CD19+ B cells IgM+ or IgM− and/or IgD+ or IgD−.
Then, 5000 IgM+ IgD+, or IgM+IgD− or IgM−IgD+, or IgM−IgD−
B cells per sample were exported for further analysis in R, by
following a script that makes use of Bioconductor libraries and
R statistical packages (CATALYST 1.10.1). The script is avail-
able at https://github.com/HelenaLC/CATALYST). The selection
of cofactor for data transformation was checked on Cytobank
(Beckman Coulter). FlowSOM (Bioconductor) was used to per-
form the metaclustering (K = 20); then, data were represented by
the dimensionality reduction method named UMAP.
In vitro stimulation and proliferation assays
For proliferation assays, thawed isolated PBMCs were labeled with
the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE,
from ThermoFisher, Eugene, OR). CFSE was used at a concen-
tration of 1 μg/mL according to standard procedures [27]. Cells
were then stimulated for 6 days with anti-CD3 plus anti-CD28
mAbs (1 μg/mL, Miltenyi Biotech, Bergisch Gladbach, Germany)
and IL-2 (10 ng/mL). Flow cytometric analyses for the identifica-
tion of cycling B cells were performed by gating CD19+ B cells, as
described below.
Statistical analysis
The high dimensional cytometric analysis was performed by
using differential discovery in high-dimensional cytometry via
C© 2020 Wiley-VCH GmbH www.eji-journal.eu
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high-resolution clustering [28,29]. Quantitative variables were
compared by Mann–Whitney. Data are represented as individual
values, means, and standard errors of the mean. Statistical
analyses were performed using Prism 6.0 (GraphPad Software
Inc., La Jolla, USA).
We have then investigated the role of B cells along with sev-
eral biochemical parameters and a crucial clinical outcome, that
is, death or discharge. For this purpose, we used the principal
component analysis (PCA), a dimension reduction method that
retains the characteristics of a data set that contribute most to its
variance, by keeping lower order principal components (PCs) and
ignoring the others. PCA uses an orthogonal transformation to
collapse the dataset containing correlated parameters to a smaller
set of linearly uncorrelated variables known as PCs (or dimen-
sion, “dim”), such that each PC is a weighted combination of all
the markers. We performed this type of analysis in order to test
whether subject classification was possible on the basis of the B-
cell profile and/or clinical data. Thus, PCA was carried out on the
clinical events (death or discharge, the so called “scores”), and a
dataset comprising 34 parameters (the “variables”) that included
SOFA score, lymphocyte/μL, B cells/μL, naive B cells/μL, age,
blood pH, pCo2 (mmHg), pO2 (mmHg), sO2 (%), pO2/FiO2 ratio,
ALT (U/L), total bilirubin (mg/dL), CK (U/L), creatinine (mg/dL),
D-Dimer (ng/mL), Hb (g/dL), white blood cells, WBC (N/μL), red
blood cells, RBC (106/μL), INR (ratio), LDH (U/L), CRP (mg/dL),
platelets (109/L), respiratory rate (breaths/minute), systolic blood
pressure (mmHg), dyastolic blood pressure (mmHg), heart rate
(beats/minute), plasma IgG or IgM level, and different percentage
of B-cell populations (naive, memory switched, memory IgM-only,
transitional, memory unswitched, total plasmablasts), neutrophils
(103/μL).
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